September 25, 2024 10:29 AM EDTUpdated September 27, 09:32 AM
News Briefing

Cor­rect­ed: Sanofi inks deal with I-Mab spin­out; Wave dis­clos­es $175M of­fer­ing on heels of DMD da­ta

ENDPOINTS

Plus, news about BioAge, Ful­crum Ther­a­peu­tics and Ar­cutis Bio­ther­a­peu­tics:

Sanofi snags Greater Chi­na rights to CD73 an­ti­body: The French phar­ma

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times